National Pension Service Purchases 263,172 Shares of Illumina, Inc. $ILMN

National Pension Service boosted its position in Illumina, Inc. (NASDAQ:ILMN) by 246.7% during the second quarter, according to the company in its most recent 13F filing with the SEC. The fund owned 369,856 shares of the life sciences company’s stock after buying an additional 263,172 shares during the quarter. National Pension Service’s holdings in Illumina were worth $65,032,000 as of its most recent filing with the SEC.

Several other institutional investors have also recently bought and sold shares of ILMN. Elyxium Wealth LLC acquired a new position in Illumina during the 4th quarter worth approximately $25,000. Fiduciary Financial Advisors acquired a new stake in shares of Illumina in the second quarter valued at approximately $26,000. Keating Financial Advisory Services Inc. acquired a new stake in shares of Illumina in the second quarter valued at approximately $32,000. Quarry LP bought a new stake in shares of Illumina in the third quarter worth $32,000. Finally, Nano Cap New Millennium Growth Fund L P acquired a new position in Illumina during the fourth quarter worth $33,000. Institutional investors own 89.42% of the company’s stock.

Illumina Price Performance

Shares of ILMN opened at $206.45 on Friday. The company has a market cap of $31.17 billion, a price-to-earnings ratio of 38.52, a PEG ratio of 2.85 and a beta of 1.46. Illumina, Inc. has a 1-year low of $88.00 and a 1-year high of $231.81. The company’s fifty day simple moving average is $200.89 and its 200 day simple moving average is $162.18. The company has a current ratio of 1.80, a quick ratio of 1.40 and a debt-to-equity ratio of 0.53.

Illumina (NASDAQ:ILMN) last announced its quarterly earnings results on Thursday, July 30th. The life sciences company reported $1.31 EPS for the quarter, beating analysts’ consensus estimates of $1.23 by $0.08. Illumina had a net margin of 18.36% and a return on equity of 29.84%. The firm had revenue of $1.16 billion during the quarter, compared to analysts’ expectations of $1.13 billion. During the same quarter last year, the company posted $1.19 earnings per share. The company’s revenue for the quarter was up 9.4% compared to the same quarter last year. Illumina has set its FY 2026 guidance at 5.300-5.400 EPS. On average, research analysts forecast that Illumina, Inc. will post 5.36 earnings per share for the current fiscal year.

Insider Transactions at Illumina

In related news, Director Keith A. Meister sold 119,501 shares of Illumina stock in a transaction dated Friday, September 4th. The stock was sold at an average price of $218.40, for a total transaction of $26,099,018.40. Following the completion of the transaction, the director owned 770,350 shares in the company, valued at approximately $168,244,440. This trade represents a 13.43% decrease in their ownership of the stock. The transaction was disclosed in a document filed with the SEC, which is accessible through this hyperlink. Also, SVP Christensen Wedel sold 1,033 shares of the business’s stock in a transaction that occurred on Tuesday, August 18th. The stock was sold at an average price of $191.52, for a total value of $197,840.16. Following the transaction, the senior vice president directly owned 14,023 shares in the company, valued at approximately $2,685,684.96. This trade represents a 6.86% decrease in their position. The SEC filing for this sale provides additional information. The transaction was executed under a pre-arranged Rule 10b5-1 trading plan. Over the last ninety days, insiders sold 2,062,465 shares of company stock worth $436,589,802. 2.90% of the stock is owned by insiders.

Analyst Ratings Changes

ILMN has been the topic of several recent research reports. UBS Group assumed coverage on shares of Illumina in a research note on Wednesday. They issued a “buy” rating and a $260.00 price target on the stock. JPMorgan Chase & Co. increased their price objective on shares of Illumina from $220.00 to $230.00 and gave the stock an “overweight” rating in a research note on Friday, July 31st. Guggenheim raised their price objective on Illumina from $200.00 to $226.00 and gave the company a “buy” rating in a report on Friday, July 31st. TD Cowen lifted their target price on Illumina from $192.00 to $210.00 and gave the company a “hold” rating in a research report on Friday, July 31st. Finally, Barclays upped their target price on Illumina from $145.00 to $160.00 and gave the stock an “underweight” rating in a report on Friday, July 31st. Ten research analysts have rated the stock with a Buy rating, six have issued a Hold rating and two have issued a Sell rating to the stock. Based on data from MarketBeat.com, the stock presently has an average rating of “Hold” and a consensus target price of $199.12.

Illumina Company Profile

Illumina, Inc develops and manufactures genomic analysis technologies used by researchers, healthcare providers, pharmaceutical companies and other organizations. Its offerings include next-generation DNA sequencing systems, microarray platforms, consumables, laboratory services and bioinformatics software designed to help analyze genetic variation and biological functions.

The company’s sequencing instruments include systems for a range of applications and throughput levels, such as the NovaSeq, NextSeq, MiSeq and iSeq platforms.